Kanis JA - Search Results

1

Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO).

Cooper C, Bardin T, Brandi ML, Cacoub P, Caminis J, Civitelli R, Cutolo M, Dere W, Devogelaer JP, Diez-Perez A, Einhorn TA, Emonts P, Ethgen O, Kanis JA, Kaufman JM, Kvien TK, Lems WF, McCloskey E, Miossec P, Reiter S, Ringe J, Rizzoli R, Saag K, Reginster JY. Cooper C, et al. Among authors: kanis ja. Aging Clin Exp Res. 2016 Feb;28(1):1-16. doi: 10.1007/s40520-015-0522-1. Epub 2016 Jan 8. Aging Clin Exp Res. 2016. PMID: 26746234 Review.

2

Epidemiology of vertebral osteoporosis.

Kanis JA, McCloskey EV. Kanis JA, et al. Bone. 1992;13 Suppl 2:S1-10. doi: 10.1016/8756-3282(92)90189-4. Bone. 1992. PMID: 1385718 Review.

3

Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption.

Taube T, Beneton MN, McCloskey EV, Rogers S, Greaves M, Kanis JA. Taube T, et al. Among authors: kanis ja. Eur J Haematol. 1992 Oct;49(4):192-8. doi: 10.1111/j.1600-0609.1992.tb00046.x. Eur J Haematol. 1992. PMID: 1464362

4

Osteoporotic fractures: an unusual presentation of haemochromatosis.

Eyres KS, McCloskey EV, Fern ED, Rogers S, Beneton M, Aaron JE, Kanis JA. Eyres KS, et al. Among authors: kanis ja. Bone. 1992;13(6):431-3. doi: 10.1016/8756-3282(92)90086-c. Bone. 1992. PMID: 1476821

5

Spontaneous fractures in a patient treated with low doses of etidronic acid (disodium etidronate).

Eyres KS, Marshall P, McCloskey E, Douglas DL, Kanis JA. Eyres KS, et al. Among authors: kanis ja. Drug Saf. 1992 Mar-Apr;7(2):162-5. doi: 10.2165/00002018-199207020-00008. Drug Saf. 1992. PMID: 1605902

6

Stanozolol stimulates remodelling of trabecular bone and net formation of bone at the endocortical surface.

Benéton MN, Yates AJ, Rogers S, McCloskey EV, Kanis JA. Benéton MN, et al. Among authors: kanis ja. Clin Sci (Lond). 1991 Oct;81(4):543-9. doi: 10.1042/cs0810543. Clin Sci (Lond). 1991. PMID: 1657503

7

Rationale for the use of bisphosphonates in bone metastases.

Kanis JA, McCloskey EV, Taube T, O'Rourke N. Kanis JA, et al. Bone. 1991;12 Suppl 1:S13-8. doi: 10.1016/8756-3282(91)90061-m. Bone. 1991. PMID: 1954047 Review.

8

Use of diphosphonates in hypercalcaemia due to malignancy.

Kanis JA, McCloskey EV, Paterson AH. Kanis JA, et al. Lancet. 1990 Jan 20;335(8682):170-1. Lancet. 1990. PMID: 1967461 No abstract available.

9

Effects of amino-butylidene diphosphonate in hypercalcemia due to malignancy.

Bickerstaff DR, O'Doherty DP, McCloskey EV, Hamdy NA, Mian M, Kanis JA. Bickerstaff DR, et al. Among authors: kanis ja. Bone. 1991;12(1):17-20. doi: 10.1016/8756-3282(91)90049-o. Bone. 1991. PMID: 2054231

10

Effects of clodronate in severe hyperparathyroid bone disease in chronic renal failure.

Hamdy NA, McCloskey EV, Brown CB, Kanis JA. Hamdy NA, et al. Among authors: kanis ja. Nephron. 1990;56(1):6-12. doi: 10.1159/000186092. Nephron. 1990. PMID: 2146521

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

876 results

Search Page

Filters